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Summary The serum and urine concentrations of a tumour-associated trypsin inhibitor, TATI, were
determined by radioimmunoassay in patients with pancreatic cancer and with benign pancreatic and biliary
diseases. Elevated serum levels (>20pug1-1) were found in 85% of the patients with pancreatic cancer, and
elevated urine levels (>50pgg-1 creatinine) in 96% of the patients. Thus low TATI level, especially in urine,
makes the possibility of pancreatic cancer less likely. Serial assay of TATI in serum from three patients with
surgically removed pancreatic cancer showed elevation of the TATI level at the time of detection of
recurrence. However, high serum and urine levels were also seen in pancreatitis and in benign extrahepatic
cholestasis. Thus TATI is a sensitive, although not specific, indicator of pancreatic and biliary disease, but the
use ofTATI as a tumour marker in the primary diagnosis ofpancreatic cancer is limited.
Immunohistochemical staining of pancreatic lesions showed that half of the pancreatic tumours expressed
TATI, but the pancreatic tissue adjacent to a carcinoma always stained stronger than the carcinoma. It
therefore seems that the main source of TATI in serum and urine of patients with pancreatic cancer are the
normal acini and not the tumour tissue. In pancreatitis the staining was intense and clearly stronger than in
normal pancreas.
The tumour-associated trypsin inhibitor, TATI, is a
6000 dalton peptide, isolated from the urine of a
patient with ovarian cancer (Stenman et al., 1982;
Huhtala et al., 1982). Elevated concentrations have
been found in the urine of patients with
gynaecological cancer, in amniotic fluid and in
some extracts from malignant tumours (Stenman et
al., 1982). TATI levels are also elevated in patients
with pancreatitis and severe pneumonia (Huhtala et
al., 1983). Determination of the N-terminal amino
acid sequence of TATI has revealed that it is
closely related or identical to the pancreatic
secretory trypsin inhibitor (PSTI) (Kazal et al.,
1948; Bartelt et al., 1977; Huhtala et al., 1982).
Elevated levels of PSTI have been found in serum
and urine of patients with pancreatitis (Eddeland &
Ohlsson, 1978; Kitahara et al., 1980; Ogawa et al.,
1980), and in serum of patients both with
pancreatic cancer and various other malignancies
(Matsuda et al., 1983; Murata et al., 1983).
Immunohistochemically PSTI has been
demonstrated in normal acinar cells, but could not
be detected in tissue specimens of pancreatic cancer
(Marks et al., 1984).
In the present work that TATI levels in serum
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and urine were measured in patients with pancreatic
cancer, acute. and chronic pancreatitis and benign
biliary diseases. Correlations have been made to
two other tumour markers, CA 19-9 and CEA,
and to CRP, amylase, bilirubin and alkaline
phosphatase.
The presence of TATI in neoplastic and non-
neoplastic pancreatic lesions was also studied by the
immunoperoxidase technique, and the tissue
expression compared with serum levels.
Materials and methods
Serum samples
Preoperative serum samples were obtained from 34
patients with pancreatic cancer. Six patients had a
local resectable tumour, all others had a locally
spread or a metastasized tumour. There were 20
well to moderately differentiated and three poorly
differentiated adenocarcinomas, one anaplastic
carcinoma, three cystadenocarcinomas, one islet cell
carcinoma and one carcinoid tumour. In 5 patients
the exact degree of differentiation of the adeno-
carcinoma could not be determined from available
cytological specimens. Repeated samples were taken
from three patients who underwent radical resection
of the tumour and who developed a recurrence
during the observation period.
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Twenty patients had acute and five chronic
pancreatitis. Sixteen patients had benign biliary
diseases, 8 of which had extrahepatic cholestasis
due to bile duct stones or benign bile duct stenosis,
3 had bile duct stones without jaundice, and 5 had
gallbladder stones.
Urine samples
Urine samples were taken from 27 of the patients
with pancreatic cancer, from 18 patients with acute
and 5 with chronic pancreatitis and from 16
patients with benign biliary disease.
Histological specimens
The following surgical specimens were studied: 8
samples of normal pancreas and 26 samples of
pancreatic tissue adjacent to chronic pancreatitis or
pancreatic cancer; 12 acute and 18 chronic
pancreatitis; 41 well to moderately differentiated
ductal adenocarcinomas (35 primary tumours and 6
metastases) and 6 poorly differentiated adeno-
carcinomas (3 primary tumours and 3 metastases);
5 anaplastic carcinomas (4 primary tumours and 1
metastasis); 4 mucinous and 3 serous cystadenomas;
3 cystadenocarcinomas; one carcinoid tumour and
8 islet cell tumours. The samples were formalin-
fixed, paraffin-embedded surgical specimens, stored
for 6 months to 10 years.
Radioimmunoassay of TATI
The concentration of TATI in serum and urine was
determined by radioimmunoassay as previously
described (Huhtala et al., 1983). The serum and
urine samples were stored at -20°C or lower
temperature until assayed. To avoid the effect of
variation in urinary excretion rate, the urinary
concentration of TATI was correlated to the
urinary creatinine concentration. The cut-off level
in serum was 20 gIg and in urine 50,gg 1
creatinine.
Immunodiffusion
The immunological identity of TATI in the urine of
patients with pancreatic cancer, pancreatitis and
benign biliary disease was studied by immuno-
diffusion. This was performed on 1Ox 1Ocm agar
plates using 0.9% agar in phosphate-buffered
(10mmolI-l, pH7.4) saline (150mmoll-1) (PBS)
containing 4% polyethylene glycol 6000 (Fluka
AG, Buchs, Switzerland).
Determination of CA 19-9, CEA, CRP, amylase,
bilirubin and alkaline phosphatase
The TATI levels were compared to CA 19-9, that
has been demonstrated to be useful as a tumour
marker in pancreatic cancer (Haglund et al., 1986),
and to CEA. The CRP level was determined as an
indicator of acute inflammation. As indicators of
juandice, extrahepatic cholestasis and of pan-
creatitis serum bilirubin, total alkaline phosphatase
and amylase were recorded.
The concentration of CA 19-9 in serum was
measured using the CA 19-9 RIA obtained from
Centocor (Malvern, PA, USA), and carcino-
embryonic antigen (CEA) using the Abbott-CEA-
RIA Diagnostic Kit (Abbott, Wiesbahn, West
Germany). A cut-off value of 37Uml-1 was used
for CA 19-9 and 2.5ngml-I for CEA. CRP was
determined by immunoturbidometry using an IL
Multistat centrifugal analyser. Antiserum and CRP
standard were purchased from Orion Diagnostica
(Helsinki, Finland). A cut-off level of 10mgI1 was
used. Serum amylase, bilirubin and alkaline
phosphatase values were obtained from clinical
records, when available. Standard cut-off values
of 300Uml -1, 20 mol 1 and 280Uml 1,
respectively, were used.
Staining procedure
Five ,um thick sections were deparaffinized,
hydrated and treated with 0.4% pepsin (2500 FIP-
Ug-1, Merck, Darmstadt, West Germany) in
0.01 NHCl for 1 h at 37°C. The sections were
incubated in 0.5% hydrogen peroxide in methanol
to block endogenous peroxidase. The sections were
then reacted with serum from rabbits immunized
with purified TATI. Bound antibody was detected
with an avidin-biotin complex assay (ABC,
Vectastain) or an indirect immunoperoxidase
technique. In the ABC-assay sections were
successively treated with non-immune horse serum,
serum containing TATI antibodies (1:50),
biotinylated anti-mouse immunoglobulin antiserum,
avidin, and biotinylated horseradish peroxidase
complex. The sections were finally exposed to 3-
amino-9-ethyl-carbazole (AEC) and hydrogen
peroxide. Using the indirect staining technique
sections were incubated with non-immune swine
serum (1:20), primary antibody (1:20), swine anti-
rabbit peroxidase conjugate (Dako, Copenhagen,
Denmark) (1:100), AEC and hydrogen peroxide.
Each step was followed by washing in PBS. All
sections were counterstained with hematoxylin.
Enhancement of the staining using pepsin
pretreatment was shown in a test series. Staining
with non-immune rabbit serum and with PBS were
used as negative controls. A known positive
specimen was used as a positive control in each
series.TATI IN PANCREATICO-BILIARY DISEASES
Results
TATI in serum and urine in pancreatic cancer
Twenty-nine of 34 patients (85%) with pancreatic
cancer had a serum TATI level above 20 g1-1.
The median value was 38ygl-1 and the range 14-
1419ugl-1. Elevated levels were also seen in serum
of five out of six patients with a local, resectable
tumour (Figure 1).
Serial samples were obtained from 3 patients.
One had an elevated preoperative serum TATI
level, which decreased after surgical removal of the
tumour, remained moderately elevated and
increased again at the time the recurrence was
clinically detected. In the other two patients the
initial serum TATI level was normal and increased
only moderately at the time of detection of the
recurrence (Figure 2).
Twenty-six of 27 patients (96%) had an elevated
urine TATI level (>50 gg-1 creatinine). The
median value was 173pgg- 1 creatinine and the
range 47-25,200pgg-1 creatinine. Urine samples
were available from 2 patients with a local tumour,
both of which had an elevated TATI level (Figure
3). Serial urine samples were available from only
one patient. The urine TATI concentration stayed
at the same level postoperatively and did not
markedly increase although a recurrence was
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Figure 2 Monitoring of serum concentrations of
TATI in patients with pancreatic cancer treated with
radical surgery. The arrows indicate the time of
clinical verification of recurrence.
103p
102
20
0
0
0
I
I
0
0
0
0
0
0
Pancreatic
cancer
0
8
0
0 0
Pancreatitis Benign biliary
disease
* Advanced * Acute * With jaundice
o Localized o Chronic o Without jaundice
Figure 1 Serum concentrations of TATI in patients
with pancreatic cancer, pancreatitis and benign biliary
diseases. The cut-off value for S-TATI is marked as a
dashed line.
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Figure 3 Urine concentrations of TATI in patients
with pancreatic cancer, pancreatitis and benign biliary
diseases. The cut-off value for U-TATI is marked as a
dashed line.
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detected. Both well and poorly differentiated ductal
adenocarcinomas were associated with elevated
levels of TATI in serum and urine. One patient
with an anaplastic carcinoma had a normal serum
level and one patient with an islet cell carcinoma
had a normal serum but an elevated urine TATI,
whereas one patient with a carcinoid tumour of the
pancreas had a very high serum TATI
concentration and a moderately elevated urine level.
TATI in serum and urine in benign diseases
Twenty-one of 25 patients (84%) with pancreatitis
had an increased serum TATI concentration. The
median value was 87jg1-1 and the range 2.2-
978MgIP1 (Figure 1). The urine level was elevated
in 16 of 23 patients (70%) with a median value of
83 igg-1 creatinine and a range of 26-
18,070pgg-1 creatinine (Figure 3).
Serum and urine concentrations of TATI were
elevated in 12 of 16 patients (75%) with benign
biliary disease. The median value for the
concentration in serum was 38.5pgl-1 and in urine
66.5,ugg- creatinine. The range was 11-216ig1-1
and 26-1,979jgg-1 creatinine, respectively (Figures
1 and 3).
Comparison of TATI and CA 19-9, CEA, CRP,
amylase, bilirubin, and alkaline phosphatase
There was a weak positive correlation (r=0.50)
between TATI concentrations in serum and urine
(Figure 4). There was no significant correlation
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Figure 4 Comparison of the concentrations of TATI
in serum and urine in patients with pancreatic cancer
(0), pancreatitis and benign biliary diseases (0). The
cut-off values are marked as dashed lines.
between S-TATI or U-TATI and CA 19-9
(r=-0.04; -0.02, respectively), CEA (r=-0.04;
-0.05), amylase (r=0.19; -0.02), bilirubin
(r=0.01; 0.30), alkaline phosphatase (r=0.01; 0.06)
or CRP (r=0.03; 0.19).
Immunodiffusion
In immunodiffusion, TATI in urine from patients
with pancreatic cancer, acute pancreatitis and
benign extrahepatic cholestasis gave identical
reactions with that in the urine of a patient with
ovarian cancer.
TATI in histological specimens
Normal pancreas Acini stained positively in
normal pancreas, but rather weakly in some
specimens. Predominantly the apical parts of the
acinar cells were positive, but in some cases a
diffuse intracytoplasmic staining was seen.
Occasionally the brush border of the ductal
epithelium was stained. Langerhans' islets were
always negative (Figure 5). Normal pancreatic
tissue adjacent to chronic pancreatitis or
carcinomas usually stained more strongly than
normal pancreas. In two of these cases even
occasional cells within Langerhans' islets stained.
Pancreatitis Acinar cells had a strong intracyto-
plasmic staining. The distribution was typically
diffuse, but in places the apical parts of the cells
stained more strongly. Positive intracytoplasmic
granules were seen in part of the cells, especially in
chronic pancreatitis. The staining was stronger in
pancreatitis than in normal pancreas. Acute
pancreatitis stained more intensely than chronic
pancreatitis. Part of both small and large ducts
stained positively at the luminal border (Figure 6).
Islets were negative in all but two cases of chronic
pancreatitis, where occasional positive cells were
seen.
Well to moderately differentiated adenocarcinomas
Nineteen out of 35 primary tumours expressed
TATI. The positivity was predominantly seen in the
apical parts of the cells, where occasionally
intensely stained positive granules were seen (Figure
7A). In places the intracytoplasmic staining was
diffuse. The positive staining was focal, and less
intense than in adjacent normal pancreatic tissue
(Figure 7B). Four liver metastases and one
metastasis from the omentum were negative. One
metastasis in the wall of the small intestine was
focally positive. In one patient both the primary
tumour and a liver metastasis were negative.TATI IN PANCREATICO-BILIARY DISEASES 301
Figure 5 Normal pancreas. Immunoperoxidase Figure 6 Acute pancreatitis. Immunoperoxidase
staining with antibodies against TATI (x 125). staining with antibodies against TATI (x 125).
Figure 7 Ductal adenocarcinoma of the pancreas. A. TATI positive tumour, B. Slightly positive tumour,
adjacent pancreatic tissue strongly positive. Immunoperoxidase staining with antibodies against TATI (x 125).
Poorly differentiated and anaplastic carcinomas All
6 primary and metastatic poorly differentiated
adenocarcinomas, as well as all 5 primary and
metastatic anaplastic carcinomas were negative.
Cystic tumours The intracytoplasmic mucin stained
positively in all 4 mucinous cystadenomas (Figure
8), but in none of the 3 mucinous cystadenocarcin-
omas. In 2 cystadenomas the staining was intense
and widely distributed, but in the other 2 weaker
and focal. All 3 serous cystadenomas were negative.
One carcinoid tumour of the pancreas as well as
all benign and malignant islet cell tumours were
negative.
Comparison between expression in tissue and serum
and urine concentration
There was no correlation between the immunohisto-
chemical expression of TATI of the tumour and the
serum and urine TATI concentrations (Table I).
Many negative tumours were associated with
elevated serum and/or urine levels.
Figure 8 Mucinous cystadenoma of the pancreas.
Imunoperoxidase staining with antibodies against
TATI (x 125).302 C. HAGLUND et al.
Table I TATI in tissue, serum and urine of patients with pancreatic cancer.
Tissuea
Patient Adjacent
Histology no. Tumour normal Serumb Urineb
Small, well-to- 1 + + 34
moderately 2 + + + 26
differentiated 3 + + + 22
adenocarcinoma 4 + + + 202 1925
5 + ++ 21 114
Large, well-to- 6 + 0 1419 0
moderately 7 - 26 154
differentiated 8 - 657 25203
adenocarcinoma 9 - 88 0
10c - 100 1955
Poorly differentiated 11 - c 2717
and anaplastic 12C - 40 130
carcinoma 13 - 18
Cystadenocarcinoma 14 - 34
15 - 33 173
16 - 16 c
Islet cell carcinoma 17 - 17 82
Carcinoid tumour 18 - 1267 164
aArbitrary scoring of distribution and intensity; bSerum TATI concentration in pgl-1
and urine concentration in jigg-1 creatinine; cTissue specimens from liver metastases;
* Serum. urine or tissue not available.
Discussion
The serum level of TATI was elevated in most of
the patients with pancreatic cancer, and the urine
level in all but one patient. However, the TATI
level in serum and urine was elevated almost as
often in benign pancreatic and biliary diseases.
Thus TATI is a sensitive, although not specific,
indicator of these conditions. By using higher cut-
off levels the tumour-specificity does not increase.
Thus TATI is of little help in the often difficult
differential diagnosis between chronic pancreatitis
and pancreatic cancer or between benign extra-
hepatic cholestasis and pancreatic cancer.
Biochemical studies have shown that TATI and
PSTI are very similar or identical (Huhtala et al.,
1982). Pancreatic secretory trypsin inhibitor, PSTI,
was originally thought to be produced only by the
pancreas. However, the excretion of TATI is
elevated in urine of patients with gynaecological
cancer (Stenman et al., 1982), and immunohisto-
chemically PSTI has been demonstrated in many
tissues (Matsuda et al., 1983; Murata et al., 1983).
Recently normal levels of TATI have been found in
serum after total pancreatectomy, further indicating
an extrapancreatic production of this trypsin
inhibitor (Halila et al., 1985). We now show that
the trypsin inhibitor in urine of patients with
pancreatic cancer, acute pancreatitis, benign
extrahepatic cholestasis and ovarian cancer are
immunologically identical.
Immunohistochemical studies of pancreatic tissue
have previously been performed with antibodies
against PSTI, demonstrating PSTI in acinar glands
but not in pancreatic cancer (Marks et al., 1984). In
our study about half of the pancreatic cancers were
positive for TATI, but the expression was often
weak and usually only focal, and the adjacent
acinar structures stained stronger than the
carcinoma. On the basis of these findings it seems
that the main source of TATI in serum and urine
of patients with pancreatic cancer are the acini and
not the tumour tissue. This is further supported
by the elevated serum and urine levels of TATI
in patients with immunohistochemically TATI
negative tumours. In one metastasis of a pancreatic
carcinoma a few positive cells were seen, in all
other cases the metastases were negative.
The tissue expression of TATI in pancreatic
tissue adjacent to a carcinoma is stronger than the
expression in normal pancreas, possibly because of
an obstruction of pancreatic ducts with congestion
of material normally secreted. An increased
production of material normally secreted. An
increased production of TATI by the acinar cells is
also possible. In acute pancreatitis the increasedTATI IN PANCREATICO-BILIARY DISEASES 303
proteolytic activity might induce an increased
production of proteolytic inhibitors. On the other
hand, the secretion could be decreased due to tissue
oedema. The source of the elevated TATI levels
seen in benign extrahepatic cholestasis is unknown.
A bile duct stone in the distal portion of the
common bile duct may cause obstruction of both
the common bile duct and the pancreatic duct,
which may explain the high serum and urine levels
of TATI in some patients. On the other hand,
TATI can also be found immunohistochemically in
biliary epithelium (Haglund et al., unpublished).
Although the main source of the high
concentrations of TATI seems to be the adjacent
benign tissue, some tumours apparently are able to
produce this trypsin inhibitor. The capacity seems
to be limited to well differentiated carcinomas. The
benign mucinous cystic tumours expressed TATI,
whereas the mucinous cystadenocarcinomas, as well
as the serous cystadenomas were negative. All
mucinous cystic tumours of the pancreas are
regarded potentially malignant (Compagno &
Oertel, 1978). It is possible that the inability to
produce TATI correlates with the degree of
malignancy of mucinous cystic tumours.
As a conclusion, a negative TATI level, especially
in urine, strongly speaks against pancreatic cancer,
but in clinical practice the low specificity limits the
use of TATI as a tumour marker to differentiate
between benign and malignant pancreatic diseases.
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